This article is
- freely available
Nanotechnology and Drug Delivery: An Update in Oncology
Department of Medicine, Emory University, 80 Jesse Hill Dr., Atlanta, GA 30303, USA
Winship Cancer Institute, Department of Medicine, Emory University, 1365 Clifton Rd, Atlanta, GA 30322, USA
* Author to whom correspondence should be addressed.
Received: 6 February 2011 / Accepted: 31 March 2011 / Published: 14 April 2011
Abstract: The field of nanotechnology has exploded in recent years with diverse arrays of applications. Cancer therapeutics have recently seen benefit from nanotechnology with the approval of some early nanoscale drug delivery systems. A diversity of novel delivery systems are currently under investigation and an array of newly developed, customized particles have reached clinical application. Drug delivery systems have traditionally relied on passive targeting via increased vascular permeability of malignant tissue, known as the enhanced permeability and retention effect (EPR). More recently, there has been an increased use of active targeting by incorporating cell specific ligands such as monoclonal antibodies, lectins, and growth factor receptors. This customizable approach has raised the possibility of drug delivery systems capable of multiple, simultaneous functions, including applications in diagnostics, imaging, and therapy which is paving the way to improved early detection methods, more effective therapy, and better survivorship for cancer patients.
Keywords: drug delivery systems; nanotechnology; cancer; passive targeting; active targeting
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Jones, T.; Saba, N. Nanotechnology and Drug Delivery: An Update in Oncology. Pharmaceutics 2011, 3, 171-185.
Jones T, Saba N. Nanotechnology and Drug Delivery: An Update in Oncology. Pharmaceutics. 2011; 3(2):171-185.
Jones, Tait; Saba, Nabil. 2011. "Nanotechnology and Drug Delivery: An Update in Oncology." Pharmaceutics 3, no. 2: 171-185.